Establishment of novel glucose tolerance marker in diabetes patients.

Establishment of novel glucose tolerance marker in diabetes patients. - Establishment of novel glucose tolerance marker in diabetes patients.(EAGLE study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003906

Enrollment

Registered

2010-07-14

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2Diabetes Mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with type 2 diabetes mellitus who have not treated or recieved medication and are to start medication or those who have been treated by alpha-glucosidase inhibitors and are to start medication by agents other than alpha-glucosidase inhibitors (2)Women who are unlikely to conceive (3)Patients who can visit in fasting condition for blood sampling (4)Patients who voluntarily provide informed consent with enough comprehension after receiving enough explanation of this study

Exclusion criteria

Exclusion criteria: (1)Type 1 diabetes mellitus (2)HbA1c>=8.0% (3)Patients with no apparent history of diabetic nephropathy, diabetic retinopathy or diabetic neuropathy (4)Patients with no history of malignancy (5)Patients with no history of serious liver disease(i.e.acute hepatitis, acute exacerbation of chronic hepatitis, hepatocirrhosis, hepatoma,jaundice,biliary obstruction) (6)Serum creatinine>=2.5mg/dl (7)Under 20 years old (8)Patients judged to be inappropriate for this study by the investigators

Design outcomes

Primary

Measure	Time frame
Changes in several biomarkers from baseline after treatment of diabetes	—

Countries

Japan

Outcome results